Mizuho Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $96

Benzinga Newsdesk www.benzinga.com Negative 93.5%

Neg 93.5% Neu 0% Pos 0%

Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and lowers the price target from $106 to $96.